Tukysa
What Tukysa is used for
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Tukysa
- Active substance
- tucatinib
- Disease area
- Breast Neoplasms; Neoplasm Metastasis
- Medicine group
- Antineoplastic agents
- ATC code
- L01EH03
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Tukysa
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tukysa used for?
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
What is the active substance in Tukysa?
Tukysa contains tucatinib.
Who makes Tukysa?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU